Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide medicament for treating highly pathogenic bird flu virus H5N1induced disease

A bird flu virus, H5N1 technology, applied in the field of biomedicine, can solve the problem of reduced replication efficiency in mice, and achieve the effect of facilitating automated mass production, convenient transportation and storage, and no toxic and side effects

Inactive Publication Date: 2009-04-22
ARMY MEDICAL UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Watanabe et al. found that after cutting off 11 amino acids at the hydroxyl end of H5N1 virus M2, the virus had similar growth ability compared with the wild type, but the replication efficiency in mice was greatly reduced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide medicament for treating highly pathogenic bird flu virus H5N1induced disease
  • Polypeptide medicament for treating highly pathogenic bird flu virus H5N1induced disease
  • Polypeptide medicament for treating highly pathogenic bird flu virus H5N1induced disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1: its amino acid sequence can be:

[0027]

[0028] The peptide can stimulate HLA-A in vitro * 0201-positive human peripheral blood mononuclear cells can increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 60%, and can also activate CTL to dissolve the highly pathogenic avian influenza virus H5N1 The cells with the H5 gene had a lysis rate of 83.10%.

Embodiment 2

[0029] Embodiment 2: its amino acid sequence can also be:

[0030]

[0031] The peptide can stimulate HLA-A in vitro * 0201-positive human peripheral blood mononuclear cells can increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 50%, and can also activate CTL to dissolve the highly pathogenic avian influenza virus H5N1 The cells with H5 gene had a lysis rate of 79.0%.

Embodiment 3

[0032] Embodiment 3: its amino acid sequence can also be:

[0033]

[0034] The peptide can stimulate HLA-A in vitro * 0201-positive human peripheral blood mononuclear cells can increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 55%, and can also activate CTL to dissolve the highly pathogenic avian influenza virus H5N1 The cells with the H5 gene had a lysis rate of 68.0%.

[0035] The amino acid sequence method described above is an existing mature technology, which is made according to the following method:

[0036] Adopt the standard Fmoc scheme, initially select 0.0125mmol, PSC resin (produced by ABI company, batch number A5F013), respectively according to the sequence characteristics described in claim 1, 2, 3 or 4, make the peptide chain extend from the C terminal to the N terminal one by one , the consumption of each amino acid raw material (produced by American ABI Company) is 0.1 mmol. Vario...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a polypeptide drug for treating diseases initiated by highly pathogenic bird flu virus H5N1. The polypeptide drug is characterized in that the amino acid sequence of the polypeptide drug is amino terminal-FLNVEWSYI-carboxyl terminal; a plurality of the amino acid sequences form a multicopy serial structure by using lysine as a joint. The polypeptide drug has the advantages of convenient transportation and storage and automatic batch production, and has the capability of activating specificity cytotoxicity T lymphocyte (CTL). The specificity CTL has a target cell which kills and dissolves H5 albumen with the highly pathogenic bird flu virus H5N1 with obvious effect without toxic side effect.

Description

(1) The technical field [0001] The invention relates to the field of biomedicine, in particular to a polypeptide drug for diseases caused by highly pathogenic avian influenza virus H5N1. (two), background technology [0002] Avian influenza (Avian influenza) is abbreviated as bird flu, which is a widespread infectious disease in poultry caused by type A influenza virus (AIV). According to incomplete statistics, the global bird flu epidemic has spread to 47 countries and regions, and there have been more than 195 cases of human bird flu, of which at least 110 people died, with a mortality rate as high as 56.4%. The avian flu that occurred in Hong Kong in 1997 caused human morbidity and death, which aroused great attention from all over the world. AIV can be divided into 16 H subtypes (H1-H16) and 10 N subtypes (N1-N10) according to the differences in the antigenicity of hemagglutinin (HA) and neuraminidase (NA). [Alexander DJ. A review of avian influenza in different birdsp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/10A61K38/16A61P31/16
Inventor 吕凤林梅虎田菲菲张一李元朝
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com